-
Electronic (PDF)
-
Site License
-
Enterprisewide
AKELA Pharma Inc. (AKLPF) - Financial and Strategic SWOT Analysis Review
GlobalData, September 2011, Pages: 41
AKELA Pharma Inc. (AKLPF) - Financial and Strategic SWOT Analysis Review
Summary
Akela Pharma Inc., (Akela) is an integrated product development company focused on developing drug delivery technologies and therapeutics for the pain market. It also provides research and development services including specialty drug manufacturing, product development & testing, analytical method development and patent litigation support services. Taifuno is the company’s Inhalation Drug Delivery Platform. The company's lead product, Fentanyl TAIFUN is a fast-acting fentanyl formulation, delivered using the company’s approved TAIFUN Multi-Dose Inhaler for the treatment of breakthrough cancer pain is in developing stage. Other products under development include Akela GHRH for Growth hormone secretion. PharmaForm, the wholly owned subsidiary of Akela, is a specialty contract service provider offering a portfolio of other innovative technologies in drug product development, manufacturing and analytical testing to the pharmaceutical and biotechnology industries. It is headquartered in Austin, Texas.
AKELA Pharma Inc. Key Recent Developments
Aug 16, 2011: Akela Pharma reports loss of $520,000 in second quarter
Dec 16, 2010: Akela Appoints Beng Lai To Board
Dec 16, 2010: Akela Appoints Beng Lai To Board
Nov 15, 2010: Akela Reports Net Income Of $0.1 Million For Q3 2010
Feb 04, 2010: Akela Announces Outcomes Of Legal Cases
This comprehensive SWOT profile of AKELA Pharma Inc. provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:
- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Key manufacturing facilities – A list of key manufacturing facilities of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Note: Some sections may be missing if data is unavailable for the company.
Key benefits of buying this profile include:
You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
List of Tables
List of Figures
Section 1 - About the Company
AKELA Pharma Inc. - Key Facts
AKELA Pharma Inc. - Key Employees
AKELA Pharma Inc. - Key Employee Biographies
AKELA Pharma Inc. - Major Products and Services
AKELA Pharma Inc. - Pharmaceutical Pipeline Products Data
AKELA Pharma Inc., Pipeline Products by Therapy Area
AKELA Pharma Inc., Pipeline Products by Development Phase
AKELA Pharma Inc. - Medical Equipment Pipeline Products Data
AKELA Pharma Inc. Pipeline Products by Equipment Type
AKELA Pharma Inc. Pipeline Products by Development Stage
AKELA Pharma Inc. - History
AKELA Pharma Inc. - Company Statement
AKELA Pharma Inc. - Locations And Subsidiaries
Head Office
AKELA Pharma Inc. - Key Manufacturing Facilities
Section 2 – Company Analysis
AKELA Pharma Inc. - Business Description
AKELA Pharma Inc. - Corporate Strategy
AKELA Pharma Inc. - SWOT Analysis
SWOT Analysis - Overview
AKELA Pharma Inc. - Strengths
Strength - Focused R&D Activities
Strength - Proprietary Drug Delivery Platforms
Weakness - Lack of Commercial Products
Weakness - Reliance on Third Parties
Opportunity - Biotech Focus
Opportunity - Market Potential
Opportunity - Expansion Plans
Threat - Uncertain R&D Outcomes
Threat - Industry Consolidation
Threat - Tightening of FDA’s Regulatory Oversight
AKELA Pharma Inc. - Key Competitors
Section 3 – Company Financial Ratios
Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts
Section 4 – Company’s Lifesciences Financial Deals and Alliances
AKELA Pharma Inc., Pharmaceuticals & Healthcare, Deals By Year, 2005 to YTD 2011
AKELA Pharma Inc., Pharmaceuticals & Healthcare, Deals By Type, 2005 to YTD 2011
AKELA Pharma Inc., Medical Equipment, Deals By Year, 2005 to YTD 2011
AKELA Pharma Inc., Medical Equipment, Deals By Type, 2005 to YTD 2011
AKELA Pharma Inc., Recent Deals Summary
Section 5 – Company’s Recent Developments
Aug 16, 2011: Akela Pharma reports loss of $520,000 in second quarter
Dec 16, 2010: Akela Appoints Beng Lai To Board
Dec 16, 2010: Akela Appoints Beng Lai To Board
Dec 16, 2010: Akela Appoints Beng Lai To Board
Nov 15, 2010: Akela Reports Net Income Of $0.1 Million For Q3 2010
Feb 04, 2010: Akela Announces Outcomes Of Legal Cases
Section 6 – Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer
Acura Pharmaceuticals, Inc.
Pain Therapeutics, Inc.
Alkermes, Inc.
Purdue Pharma L.P.
Elite Pharmaceuticals, Inc.
Collegium Pharmaceutical, Inc.
Egalet a/s
DURECT Corporation
Customers who bought this item also bought
All rights reserved. © Copyright 2013 Research and Markets WWW5
Terms and Conditions Privacy Policy Publishers Employment Opportunities Site Map Link to us Webmaster Affiliate Network
